RDY Quote, Financials, Valuation and Earnings

HDFC Bank has a net margin of 18.73% compared to Dr Reddy's Laboratories's net margin of 25.7%. Dr Reddy's Laboratories's return on equity of 18.25% beat HDFC Bank's return on equity of 12.02%.

Dr Reddy's Laboratories has a consensus price target of $14.42, signalling upside risk potential of 2.26%. On the other hand HDFC Bank has an analysts' consensus of $78.23 which suggests that it could grow by 8.06%. Given that HDFC Bank has higher upside potential than Dr Reddy's Laboratories, analysts believe HDFC Bank is more attractive than Dr Reddy's Laboratories.

Dr Reddy's Laboratories has a beta of 0.326, which suggesting that the stock is 67.42% less volatile than S&P 500. In comparison HDFC Bank has a beta of 0.629, suggesting its less volatile than the S&P 500 by 37.054%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.68%. HDFC Bank offers a yield of 0.96% to investors and pays a quarterly dividend of $0.70 per share. Dr Reddy's Laboratories pays 11.78% of its earnings as a dividend. HDFC Bank pays out 20.94% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $982M, which are smaller than HDFC Bank quarterly revenues of $8.5B. Dr Reddy's Laboratories's net income of $183.9M is lower than HDFC Bank's net income of $2.2B. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 21.46x while HDFC Bank's PE ratio is 22.21x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.06x versus 6.61x for HDFC Bank. Usually stocks with elevated PS ratios are considered overvalued.

Sify Technologies has a net margin of 18.73% compared to Dr Reddy's Laboratories's net margin of -5.96%. Dr Reddy's Laboratories's return on equity of 18.25% beat Sify Technologies's return on equity of -0.19%.

Dr Reddy's Laboratories has a consensus price target of $14.42, signalling upside risk potential of 2.26%. On the other hand Sify Technologies has an analysts' consensus of $14.00 which suggests that it could grow by 215.32%. Given that Sify Technologies has higher upside potential than Dr Reddy's Laboratories, analysts believe Sify Technologies is more attractive than Dr Reddy's Laboratories.

Dr Reddy's Laboratories has a beta of 0.326, which suggesting that the stock is 67.42% less volatile than S&P 500. In comparison Sify Technologies has a beta of 1.003, suggesting its more volatile than the S&P 500 by 0.319%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.68%. Sify Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.78% of its earnings as a dividend. Sify Technologies pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $982M, which are larger than Sify Technologies quarterly revenues of $112M. Dr Reddy's Laboratories's net income of $183.9M is higher than Sify Technologies's net income of -$6.7M. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 21.46x while Sify Technologies's PE ratio is 352.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.06x versus 0.60x for Sify Technologies. Usually stocks with elevated PS ratios are considered overvalued.

SS Innovations International has a net margin of 18.73% compared to Dr Reddy's Laboratories's net margin of --. Dr Reddy's Laboratories's return on equity of 18.25% beat SS Innovations International's return on equity of --.

Dr Reddy's Laboratories has a consensus price target of $14.42, signalling upside risk potential of 2.26%. On the other hand SS Innovations International has an analysts' consensus of -- which suggests that it could fall by --. Given that Dr Reddy's Laboratories has higher upside potential than SS Innovations International, analysts believe Dr Reddy's Laboratories is more attractive than SS Innovations International.

Dr Reddy's Laboratories has a beta of 0.326, which suggesting that the stock is 67.42% less volatile than S&P 500. In comparison SS Innovations International has a beta of -69.183, suggesting its less volatile than the S&P 500 by 7018.304%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.68%. SS Innovations International offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.78% of its earnings as a dividend. SS Innovations International pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $982M, which are larger than SS Innovations International quarterly revenues of --. Dr Reddy's Laboratories's net income of $183.9M is higher than SS Innovations International's net income of --. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 21.46x while SS Innovations International's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.06x versus 89.07x for SS Innovations International. Usually stocks with elevated PS ratios are considered overvalued.

Zai Lab has a net margin of 18.73% compared to Dr Reddy's Laboratories's net margin of -45.49%. Dr Reddy's Laboratories's return on equity of 18.25% beat Zai Lab's return on equity of -33.29%.

Dr Reddy's Laboratories has a consensus price target of $14.42, signalling upside risk potential of 2.26%. On the other hand Zai Lab has an analysts' consensus of $54.59 which suggests that it could grow by 90.74%. Given that Zai Lab has higher upside potential than Dr Reddy's Laboratories, analysts believe Zai Lab is more attractive than Dr Reddy's Laboratories.

Dr Reddy's Laboratories has a beta of 0.326, which suggesting that the stock is 67.42% less volatile than S&P 500. In comparison Zai Lab has a beta of 1.037, suggesting its more volatile than the S&P 500 by 3.742%.

Dr Reddy's Laboratories has a quarterly dividend of $0.10 per share corresponding to a yield of 0.68%. Zai Lab offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Dr Reddy's Laboratories pays 11.78% of its earnings as a dividend. Zai Lab pays out -- of its earnings as a dividend. Dr Reddy's Laboratories's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Dr Reddy's Laboratories quarterly revenues are $982M, which are larger than Zai Lab quarterly revenues of $106.5M. Dr Reddy's Laboratories's net income of $183.9M is higher than Zai Lab's net income of -$48.4M. Notably, Dr Reddy's Laboratories's price-to-earnings ratio is 21.46x while Zai Lab's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Dr Reddy's Laboratories is 3.06x versus 6.95x for Zai Lab. Usually stocks with elevated PS ratios are considered overvalued.